The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.
Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia
Open accessPublished version of a preprint
Abstract
Gilteritinib is a potent and selective FLT3 kinase inhibitor with single-agent clinical efficacy in relapsed/refractory FLT3-mutated acute myeloid leukemia (AML). In this context, however, gilteritinib is not curative, and response duration is limited by the development of secondary resistance. To evaluate resistance mechanisms, we analyzed baseline and progression samples from patients treated on clinical trials of gilteritinib. Targeted next-generation sequencing at the time of AML progression on gilteritinib identified treatment-emergent mutations that activate RAS/MAPK pathway signaling, most commonly in NRAS or KRAS. Less frequently, secondary FLT3-F691L gatekeeper mutations or BCR–ABL1 fusions were identified at progression. Single-cell targeted DNA sequencing revealed diverse patterns of clonal selection and evolution in response to FLT3 inhibition, including the emergence of RAS mutations in FLT3-mutated subclones, the expansion of alternative wild-type FLT3 subclones, or both patterns simultaneously. These data illustrate dynamic and complex changes in clonal architecture underlying response and resistance to mutation-selective tyrosine kinase inhibitor therapy in AML. Significance: Comprehensive serial genotyping of AML specimens from patients treated with the selective FLT3 inhibitor gilteritinib demonstrates that complex, heterogeneous patterns of clonal selection and evolution mediate clinical resistance to tyrosine kinase inhibition in FLT3-mutated AML. Our data support the development of combinatorial targeted therapeutic approaches for advanced AML. See related commentary by Wei and Roberts, p. 998. This article is highlighted in the In This Issue feature, p. 983
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, clinical response duration to FLT3 inhibitor treatment remains short partially due to the development of secondary resistance [130].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [130]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Genomic classification and prognosis in acute myeloid leukemia
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
Stone, R. M., Mandrekar, S. J., Sanford, B. L., Laumann, K., Geyer, S., Bloomfield, C. D., Thiede, C., Prior, T. W., Döhner, K., Marcucci, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614359 · Cited by 2,250
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., et al. (2012) · Nature · doi:10.1038/nature10738 · Cited by 1,993
Grimwade, D. J., Hills, R. K., Moorman, A. V., Walker, H., Chatters, S., Goldstone, A. H., Wheatley, K., Harrison, C. J., & Burnett, A. K. (2010) · Blood · doi:10.1182/blood-2009-11-254441 · Cited by 1,936
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S. M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300874 · Cited by 1,611
The origin and evolution of mutations in acute myeloid leukemia
Welch, J. S., Ley, T. J., Link, D. C., Miller, C. A., Larson, D. E., Koboldt, D. C., Wartman, L. D., Lamprecht, T. L., Liu, F., Xia, J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.023 · Cited by 1,575
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
Yamamoto, Y. (2001) · Blood · doi:10.1182/blood.v97.8.2434 · Cited by 1,152
Fröhling, S., Schlenk, R. F., Breitruck, J., Benner, A., Kreitmeier, S., Tobis, K., Döhner, H., & Döhner, K. (2002) · Blood · doi:10.1182/blood-2002-05-1440 · Cited by 873
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Smith, C. C., Wang, Q., Chin, C.-S., Salerno, S. N., Damon, L. E., Levis, M. J., Perl, A. E., Travers, K. J., Wang, S., Hunt, J. P., et al. (2012) · Nature · doi:10.1038/nature11016 · Cited by 738
Self-citation
Research works printed but not linked: 1
- Cortes, 2018, Quizartinib significantly prolongs overall survival in patients with FLT3-internal tandem duplication–mutated relapsed/refractory AML in the phase 3, randomized, controlled QuANTUM-R trial [abstract]
Cited by
Sorted by citations
Items 401–447 of 447
Li, K.-X., Wu, H.-Y., Pan, W.-Y., Guo, M.-Q., Qiu, D.-Z., He, Y., Li, Y., Yang, D.-H., & Huang, Y.-X. (2022) · Figshare · doi:10.6084/m9.figshare.19311700
Li, K.-X., Wu, H.-Y., Pan, W.-Y., Guo, M.-Q., Qiu, D.-Z., He, Y., Li, Y.-H., Yang, D.-H., & Huang, Y.-X. (2022) · Figshare · doi:10.6084/m9.figshare.19311661
Li, K.-X., Wu, H.-Y., Pan, W.-Y., Guo, M.-Q., Qiu, D.-Z., He, Y., Li, Y., Yang, D.-H., & Huang, Y.-X. (2022) · Figshare · doi:10.6084/m9.figshare.19311652
Li, K.-X., Wu, H.-Y., Pan, W.-Y., Guo, M.-Q., Qiu, D.-Z., He, Y., Li, Y.-H., Yang, D.-H., & Huang, Y.-X. (2022) · Figshare · doi:10.6084/m9.figshare.19311670
Liccardo, F., Śniegocka, M., Tito, C., Iaiza, A., Ottone, T., Divona, M., Travaglini, S., Mattei, M., Cicconi, R., Miglietta, S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24070136
Li, K.-X., Wu, H.-Y., Pan, W.-Y., Guo, M.-Q., Qiu, D.-Z., He, Y., Li, Y., Yang, D.-H., & Huang, Y.-X. (2022) · Figshare · doi:10.6084/m9.figshare.19311682
Li, K.-X., Wu, H.-Y., Pan, W.-Y., Guo, M.-Q., Qiu, D.-Z., He, Y., Li, Y.-H., Yang, D.-H., & Huang, Y.-X. (2022) · Figshare · doi:10.6084/m9.figshare.19311697
Zhang, Y., Wang, P., Wang, Y., & Shen, Y. (2023) · Figshare · doi:10.6084/m9.figshare.22605016
Li, K.-X., Wu, H.-Y., Pan, W.-Y., Guo, M.-Q., Qiu, D.-Z., He, Y., Li, Y.-H., Yang, D.-H., & Huang, Y.-X. (2022) · Figshare · doi:10.6084/m9.figshare.19311667
Li, K.-X., Wu, H.-Y., Pan, W.-Y., Guo, M.-Q., Qiu, D.-Z., He, Y., Li, Y.-H., Yang, D.-H., & Huang, Y.-X. (2022) · Figshare · doi:10.6084/m9.figshare.19311688
Li, K.-X., Wu, H.-Y., Pan, W.-Y., Guo, M.-Q., Qiu, D.-Z., He, Y., Li, Y.-H., Yang, D.-H., & Huang, Y.-X. (2022) · Figshare · doi:10.6084/m9.figshare.19311655
Li, K.-X., Wu, H.-Y., Pan, W.-Y., Guo, M.-Q., Qiu, D.-Z., He, Y., Li, Y., Yang, D.-H., & Huang, Y.-X. (2022) · Figshare · doi:10.6084/m9.figshare.19311646
Hu, C., Zhang, Y., Yang, J., Xu, Y., 邓婷芬, Li, Y., Xu, S., Wang, S., & Wang, P. (2024) · Figshare · doi:10.6084/m9.figshare.26211429
Li, K.-X., Wu, H.-Y., Pan, W.-Y., Guo, M.-Q., Qiu, D.-Z., He, Y., Li, Y.-H., Yang, D.-H., & Huang, Y.-X. (2022) · Figshare · doi:10.6084/m9.figshare.19311685
Li, K.-X., Wu, H.-Y., Pan, W.-Y., Guo, M.-Q., Qiu, D.-Z., He, Y., Li, Y., Yang, D.-H., & Huang, Y.-X. (2022) · Figshare · doi:10.6084/m9.figshare.19311649
Resistance is not futile: RAS inhibition resensitizes AML
Collins, C. T., & Majeti, R. (2026) · Blood · doi:10.1182/blood.2025031932
Searching the druggable genome using large language models
Schimmelpfennig, L., Cannon, M., Cody, Q., McMichael, J. F., Coffman, A. C., Kiwala, S., Krysiak, K., Wagner, A. H., Griffith, M., & Griffith, O. (2026) · Bioinformatics · doi:10.1093/bioinformatics/btag632
Pang, H., Zhang, Z., Lv, X., Ge, S., Huang, Y., Qiu, Q., Wu, D., Xue, S.-L., & Liu, S.-B. (2026) · Journal of International Medical Research · doi:10.1177/03000605251412963
Ge, S., Qiu, Q.-C., 华京生, Wang, J., Yang, M., Du, J., Huang, Y.-H., Wan, C., Liu, L.-L., Dai, H., et al. (2026) · iScience · doi:10.1016/j.isci.2026.115219 · Cited by 1
Al-Shibly, R., Benkhadra, M., & Yassin, M. A. (2026) · Oncology · doi:10.1159/000551702
Caractérisation de nouvelles dépendances oncogéniques dans les hémopathies myéloïdes
Roux, B. (2022) · theses.fr (ABES) · doi:10.70675/d76b6764z8851z423dza26fz9f68e953227e
Origin and pronostic impact of intra-leukemic heterogeneity in acute myeloid leukemias
Duchmann, M. (2022) · theses.fr (ABES) · doi:10.70675/74f56644z3676z489bz8e12z27fa072401b7
SCOPE: Localizing fate-decision states and their regulatory drivers in single-cell differentiationPreprint
Zhao, Y., Finkbeiner, C., Setty, M. N., & Lin, K. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.07.717037
de Miranda, L. B. L., Lima, K., Pereira-Martins, D. A., Cortês, L. G. F., Tomaz, V., Cortes, L., Silva, M. D. F. B., Guedes, R. L. M., Campregher, P. V., Sternadt, D., et al. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178877
Tang, Y. D., Li, J., Ye, W. S., Du, Y., Zhang, Y., Yang, Y., Ye, Y., & Gong, Y. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s588865
Kawczak, P., Kawczak, K., & Bączek, T. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15134886
FLT3 inhibitors in AML: from classic scaffolds to next-generation approaches
Elmenier, F. M., Dokla, E. M. E., Samir, N., Lasheen, D. S., Abouzid, K. A. M., & Ella, D. A. A. E. (2026) · RSC Advances · doi:10.1039/d6ra01319h
Ribonucleotide Reductase Inhibition Overcomes FLT3 Inhibitor Resistance in Acute Myeloid LeukemiaPreprint
Tian, Z., Wei, X., Chatla, S., Liu, Y., Kim, D., Li, Y., Wang, P., Liao, Y., Liu, X., Yang, D., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.21.736123
Self-citationCRISPR integration of an FLT3 CAR into the TRAC locus generates CAR T cells for AML
Noer, M. G., Christensen, K. B., Mikkelsen, N. S., Skjelbostad, S. F., Rothemejer, F. H., Wittenborn, T. R., Fammé, S., Mikkelsen, K., Barington, T., Thomsen, M. K., et al. (2026) · Genome Medicine · doi:10.1186/s13073-026-01718-7
Takaoka, K., Mott, S., Yodsuwan, R., Saowapa, S., Tanariyakul, M., Wannaphut, C., & Poonsombudlert, K. (2026) · European Journal Of Haematology · doi:10.1111/ejh.70270
Irifune, H., Semba, Y., Uehara, Y., Ohta, T., Sugio, Y., Akashi, K., Maeda, T., & Ohno, Y. (2026) · Annals of Hematology · doi:10.1007/s00277-026-07196-6
Shen, L., Fan, J., Wang, N., Wang, Z., Yang, Y., Xu, C., Liu, S., Zhang, D., Fang, Y., Chu, B., et al. (2026) · Leukemia · doi:10.1038/s41375-026-03079-x
Chen, M., Chen, Y., Wang, S., Yang, F., Zheng, J., Fu, D., Lin, J., Li, X., & Li, N. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.07.015
The eco-evolutionary dynamics of acute myeloid leukemia: From clonal games to clinical intervention
Ye, C., Fu, S., Li, J., Xue, J., & Li, J. (2026) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2026.101349
Arora, S., Daver, N. G., Ravandi, F., & Short, N. J. (2026) · Expert Review of Hematology · doi:10.1080/17474086.2026.2720126
Wilson, E., Jong, F. D., & Peters, L. (2025) · Interdisciplinary Research in Medical Sciences Specialty · doi:10.51847/ck7mscpl6m
Wang, S., Zhang, Y., Zhong, Z., He, J., Fan, J., Xiang, Q., FangFang, Y., Zhang, Y., Wang, S., & Wang, P. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00561-x
Re, M. D., Wijngaarden, M. J., Frioni, F., Malara, T., Rafaniello, C., Giammarco, S., Metafuni, E., Minnella, G., Rossi, M., Capuano, A., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10700842/v1
Yang, Y. (2026) · Journal of Clinical Investigation · doi:10.1172/jci212370
Panzeca, G., Tardiolo, N., Butini, S., Gemma, S., Carullo, G., & Campiani, G. (2026) · Medicinal Research Reviews · doi:10.1002/med.70113
BindingDB Entry 50020950: Overcoming Secondary Mutations of Type II Kinase Inhibitors.
BindingDB (2025) · UC San Diego · doi:10.7270/q25t3r2k
BindingDB Entry 50018558: Targeting Gatekeeper Mutations for Kinase Drug Discovery.
BindingDB (2024) · UC San Diego · doi:10.7270/q25t3qqp
BindingDB (2024) · UC San Diego · doi:10.7270/q20p1467
Metadata
- Authors
- McMahon, C. M., Ferng, T., Canaani, J., Wang, E. S., Morrissette, J. J. D., Eastburn, D. J., Pellegrino, M., Durruthy-Durruthy, R., Watt, C. D., Asthana, S., Lasater, E. A., DeFilippis, R., Peretz, C. A. C., McGary, L. H. F., Deihimi, S., Logan, A. C., Luger, S. M., Shah, N. P., Carroll, M., Smith, C. C., & Perl, A. E.
- Affiliations
- University of Pennsylvania (US)
- University of California, San Francisco (US)
- Tel Aviv University (IL)
- Roswell Park Comprehensive Cancer Center (US)
- Mission Bio (United States) (US)
- United States Department of Veterans Affairs (US)
- ORCID
- Venue
- Cancer Discovery
- Published
- 2019-08-01
- Volume
- 9
- Issue
- 8
- Pages
- 1050-1063
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC11994087
- OpenAlex
- W2946259536
- Cited by
- 446
- References
- 35
- Citations by year
- 2026: 35 · 2025: 55 · 2024: 56 · 2023: 62 · 2022: 91 · 2021: 61 · 2020: 68 · 2019: 16
- FWCI
- 41.51
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- HHS | NIH | National Center for Advancing Translational SciencesHHS | NIH | National Center for Advancing Translational Sciences (NCATS) (TL1TR001880)
- American Society of Clinical OncologyAmerican Society of Clinical Oncology (ASCO)
- HHS | NIH | National Cancer InstituteHHS | NIH | National Cancer Institute (NCI) (R21 CA198621, R01 CA198089, R01 CA166616, K08 CA187577)
- Damon Runyon Cancer Research FoundationDamon Runyon Cancer Research Foundation (Damon Runyon) (CI-99-18)
- Biff Ruttenberg Foundation
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Keywords
- acute myeloid leukemia, FLT3 mutation, gilteritinib, FLT3 inhibitor resistance, clonal selection, clonal evolution, NRAS mutation, KRAS mutation, BCR-ABL fusion gene, tyrosine kinase inhibitor resistance, single-cell DNA sequencing
- MeSH terms
- Adult, Aged, Aged, 80 and over, Aniline Compounds, Female, Humans, Male, Middle Aged, Mutation, Pyrazines, Signal Transduction, Leukemia, Myeloid, Acute, ras Proteins, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, fms-Like Tyrosine Kinase 3, Young Adult, Single-Cell Analysis, High-Throughput Nucleotide Sequencing, Clonal Evolution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
